Frontlight ResearchEarly access
WithdrawnEarly phase 1
Fecal Microbiota Transplantation (FMT) in Treatment of Severe and Enduring Anorexia Nervosa
Key facts
- Who runs it
- University of North Carolina, Chapel Hill
- Where
- Chapel Hill, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Phase
- Early phase 1
- Started
- 1 Apr 2023
- Ended
- Sept 2024
- Type of study
- Interventional
- Treatments tested
- Fecal Microbiota Transplantation (FMT)
- Record updated
- 30 January 2023
- Why it stopped
- Withdrawn due to covid-19 protocols on inpatient eating disorders unit.
Who can take part
- Age
- 18 years to 45 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
Show the full registry criteria (32)Hide the full registry criteria
Who can take part
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Female aged 18-45
- Diagnosed with SE-AN, defined here as having suffered from AN for five or more years and having participated in two or more inpatient or residential treatment programs followed by weight relapse
- Sufficiently medically stable to receive FMT (serum electrolytes within normal limits, normal EKG)
- Willing to adhere to the FMT dosing regimen
- For females of reproductive potential, in sexual relationships with men, must use an acceptable method of contraception from 30 days prior to enrollment until 4 weeks after completing study treatment.* Participants must also be willing to be subjected to periodic pregnancy tests
- Agreement to adhere to Lifestyle Considerations throughout study duration
- Adequate insurance to cover inpatient stay; Lifestyle Considerations: During this study, participants are asked to:; Participate in standard inpatient treatment at UNC-Chapel Hill's CEED; Remain nil per os (npo) on the morning of each dosing session and for two hours after receiving FMT, on four individual instances of FMT administration; Abstain from sexual activity or use a condom or other form of highly effective birth control during the 30-day active stage of the clinical trial; Inform the research team as soon as possible if they become pregnant during the eight-week and six-month follow-up periods; If a trial participant has begun a course of one of this trial's prohibited medications during the eight-week or six-month follow-up periods, participants will be asked only to report the name of the medication, dose, and duration of treatment
Who cannot take part
- Previous FMT or microbiome-based products at any time excluding this study
- Patient received antibiotics in the last 48 hours. Patients will be eligible to enroll if antibiotic therapy is discontinued for at minimum 48 hours prior to start of study
- Concurrent intensive induction chemotherapy, radiation therapy, or biological treatment for active malignancy
- Treatment with another investigational drug within the past month
- Alcohol or drug dependence either at time of the study or within the last year
- Major gastrointestinal surgery (e.g. significant bowel resection) within 3 months before enrollment. This does not include appendectomy or cholecystectomy
- Solid organ transplant recipients less than or equal to 90 days posttransplant or on active treatment for rejection
- Patients with allergies to ingredients Generally Recognized As Safe (GRAS)
- Patients with a history of severe anaphylactic or anaphylactoid food allergy
- Febrile illness within past month
- Active gastrointestinal infection at time of enrollment
- Any gastrointestinal or potentially intestinal microbiota-related conditions, including: Severe gastroparesis (e.g., gastric pacemaker) and any history of gastrointestinal illness (including but not limited to inflammatory bowel disease, irritable bowel syndrome, celiac disease, any gastrointestinal cancer, etc.)
- Type 1 or 2 diabetes mellitus
- History of total colectomy or bariatric surgery
- If at risk for CMV/EBV associated disease (at investigator's discretion, e.g. immunocompromised), negative IgG testing for cytomegalovirus (CMV) or Epstein-Barr Virus (EBV)
- A condition that would jeopardize the safety or rights of the subject, would make it unlikely for the subject to complete the study, or would confound the results of the study
- Male or outside of the 18-45 range
- Requires continued antibiotic use or anticipates antibiotic use in the upcoming 4 weeks
- Pregnancy or lactation
- Known or suspected toxic megacolon and/or known small bowel ileus
- Patients who are immunocompromised
- Unable or unwilling to comply with protocol requirements
- Expected life expectancy < 6 months
Where in United States
- UNC- Chapel HillChapel Hill, United States
About the trial
What the trial wants to find out
This is an open-label pilot study designed to explore the safety, feasibility, tolerability, and acceptability of fecal microbiota transplantation (FMT) in the treatment of severe and enduring anorexia nervosa (SE-AN).
The group in the trial
- FMT for SE-ANTreatment being tested
Inpatients at the UNC-Chapel Hill Center of Excellence for Eating Disorders (CEED) and will receive weekly fecal microbiota transplantations for four weeks. This will be in addition to standard care at CEED.
Treatment: Fecal Microbiota Transplantation (FMT)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Safety and Efficacy of Fecal Microbiota Transplantation (FMT) in the Treatment of Severe and Enduring Anorexia Nervosa (SE-AN)
- Record updated
- 30 January 2023